2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 1/2
1
Status
Completed
4
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Gastrointestinal
3
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Platinum Resistant Ovarian Cancer
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Carcinoma
1
Adenoviridae Infections
1
Interventions
Cyclophosphamide
3162
Cisplatin
3160
Carboplatin
2938
Paclitaxel
2673
Radiotherapy
2648
Gemcitabine
2547
pembrolizumab
2331
Docetaxel
2157
Bevacizumab
2128
Fluorouracil
1822
Capecitabine
1784
Oxaliplatin
1713
Dexamethasone
1590
Nivolumab
1517
Doxorubicin
1477
Rituximab
1454
Etoposide
1342
Magnetic Resonance Spectroscopy
1266
Irinotecan
1235
Leucovorin
1216
Cytarabine
1123
Pemetrexed
1062
Drug Therapy
1062
fludarabine
1050
Vincristine
956
Specimen Handling
936
Prednisone
926
Cetuximab
921
Lenalidomide
916
Trastuzumab
902
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Interventional
×
enadenotucirev
×
Clear all
NCT03916510
2025-02-06
CEDAR
University of Oxford
Phase 1
Completed
12 enrolled
13 charts
NCT02636036
2021-11-09
SPICE
Akamis Bio
Phase 1
Completed
51 enrolled
NCT02028117
2021-05-13
OCTAVE
Akamis Bio
Phase 1
Completed
38 enrolled
NCT02028442
2020-03-12
EVOLVE
Akamis Bio
Phase 1/2
Completed
61 enrolled